Literature DB >> 32081200

The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.

Hua Jiang1, Tao Gong2, Rongbin Zhou3.   

Abstract

The NLRP3 inflammasome is a cytoplasmic multiprotein complex, the assembly of which can be initiated in response to various exogenous or endogenous danger signals. Excessive activation of the NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of human inflammatory diseases, suggesting that the NLRP3 inflammasome is a potential target for the treatment of these diseases. However, clinical drugs targeting the NLRP3 inflammasome are still not available. Recent data have elucidated the different signaling pathways or events that can control NLRP3 inflammasome activation and have provided some potential compounds with anti-NLRP3 inflammasome activity. Here, we summarize the molecular mechanisms and diseases involved in NLRP3 inflammasome activation and discuss the potential strategies targeting different aspects of the NLRP3 inflammasome and its implications for the treatment of inflammatory diseases.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammatory diseases; Inhibitors; Molecular mechanisms; NLRP3 inflammasome; Targeting strategies

Mesh:

Substances:

Year:  2019        PMID: 32081200     DOI: 10.1016/bs.ai.2019.11.003

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  13 in total

1.  CCDC50 suppresses NLRP3 inflammasome activity by mediating autophagic degradation of NLRP3.

Authors:  Yuxin Lin; Zibo Li; Yicheng Wang; Tian Tian; Penghui Jia; Yu Ye; Miao He; Zixiao Yang; Chunmei Li; Deyin Guo; Panpan Hou
Journal:  EMBO Rep       Date:  2022-03-28       Impact factor: 9.071

2.  Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma.

Authors:  Ming Ma; Guoyang Li; Minghui Qi; Wei Jiang; Rongbin Zhou
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

3.  NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway.

Authors:  Biao Tang; Dan Liu; Lingyu Chen; Yu Liu
Journal:  J Inflamm (Lond)       Date:  2020-06-24       Impact factor: 4.981

4.  Piperlongumine Is an NLRP3 Inhibitor With Anti-inflammatory Activity.

Authors:  Jie Shi; Yang Xia; Huihong Wang; Zhongjie Yi; Ruoruo Zhang; Xiufeng Zhang
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.810

5.  The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3.

Authors:  Tiantian Tang; Ping Li; Xinhui Zhou; Rui Wang; Xiuqin Fan; Mengyi Yang; Kemin Qi
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

Review 6.  Mitochondria as a Cellular Hub in Infection and Inflammation.

Authors:  Pauline Andrieux; Christophe Chevillard; Edecio Cunha-Neto; João Paulo Silva Nunes
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

Review 7.  Neuroinflammation in Alzheimer's Disease.

Authors:  Isaac G Onyango; Gretsen V Jauregui; Mária Čarná; James P Bennett; Gorazd B Stokin
Journal:  Biomedicines       Date:  2021-05-07

Review 8.  Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms.

Authors:  Jinyun Shi; Jia Guo; Zhidong Li; Baohui Xu; Masaaki Miyata
Journal:  J Atheroscler Thromb       Date:  2021-03-06       Impact factor: 4.928

9.  Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Authors:  Simone Gastaldi; Valentina Boscaro; Eleonora Gianquinto; Christina F Sandall; Marta Giorgis; Elisabetta Marini; Federica Blua; Margherita Gallicchio; Francesca Spyrakis; Justin A MacDonald; Massimo Bertinaria
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

10.  Salmonella spvC Gene Inhibits Autophagy of Host Cells and Suppresses NLRP3 as Well as NLRC4.

Authors:  Liting Zhou; Yuanyuan Li; Song Gao; Haibo Yuan; Lingli Zuo; Chaoyi Wu; Rui Huang; Shuyan Wu
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.